GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2-Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study Meeting Abstract
| Authors: | Xu, R. H.; Dongsheng, Z.; Ajani, J.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P.; Ilson, D.; Kim, S.; Lordick, F.; Shitara, K.; Van Cutsem, E.; Arozullah, A.; Park, J. W.; Shah, M. |
| Abstract Title: | GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2-Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study |
| Meeting Title: | 2019 ESMO Asia Congress |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 9 |
| Meeting Dates: | 2019 Nov 22-24 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-11-01 |
| Start Page: | mdz422.073 |
| Language: | English |
| ACCESSION: | WOS:000503487700192 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz422.073 |
| Notes: | Meeting Abstract: 197TiP -- Appears on pages ix65-ix66 of the abstract book -- Source: Wos |
